Imago BioSciences, a Phase 2 biotech developing small molecules for bone marrow cancers and diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Imago Biosciences is discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. Its lead product candidate, bomedemstat, is being advanced for the treatment of myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. Bomedemstat has completed enrollment of a Phase 2 trial in patients with an MPN known as myelofibrosis, and is currently enrolling patients in a Phase 2 trial in patients with an MPN known as essential thrombocythemia.
The South San Francisco, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol IMGO. Jefferies, Cowen, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
